Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Nanjing Leads Biolabs Co: Clinical Trials & FDA Approval Profile

Nanjing Leads Biolabs Co (Global / Institutional) sponsors 17 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 12 active protocols (11 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)26 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Nanjing Leads Biolabs Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)17
Active Pipeline (Recruiting Now)12 (11)
Completed vs Stopped Early5 / 0 (0.0%)
Median Closed Actual Enrollment26 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Nanjing Leads Biolabs Co
Hospital Research SiteLocationShared Protocols
Henan Cancer HospitalZhengzhou, Henan11
Shandong Cancer HospitalJinan, Shandong10
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong10

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Nanjing Leads Biolabs Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07111546A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]Phase IIRECRUITING
NCT06783647A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]Phase IIRECRUITING
NCT07390383A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]Phase IIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Nanjing Leads Biolabs Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI